ABIVAX
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (obefazimod) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-17 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | |
| 2025-06-19 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | |
| 2025-06-11 22:00 |
Declaration of Voting Results & Voting Rights Announcements
Abivax Announces Results of its June 6, 2025 Annual General Meeting
|
English | 106.1 KB | |
| 2025-06-11 22:00 |
Declaration of Voting Results & Voting Rights Announcements
Abivax annonce les résultats de son Assemblée Générale du 6 juin 2025
|
French | 81.2 KB | |
| 2025-06-11 22:00 |
Earnings Release
Abivax Announces Results of its June 6, 2025 Annual General Meeting
|
English | 10.1 KB | |
| 2025-06-10 15:06 |
Declaration of Voting Results & Voting Rights Announcements
Franchissements de seuils
|
French | 130.6 KB | |
| 2025-06-02 22:00 |
Earnings Release
Abivax présente ses résultats financiers du premier trimestre 2025
|
French | 276.0 KB | |
| 2025-06-02 22:00 |
Interim Report
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2…
|
French | 5.5 MB | |
| 2025-06-02 22:00 |
Earnings Release
Abivax Presents First Quarter 2025 Financial Results
|
English | 22.5 KB | |
| 2025-06-02 22:00 |
Earnings Release
Abivax presente ses resultats financiers du premier trimestre 2025
|
French | 73.4 KB | |
| 2025-06-02 00:00 |
Interim Report
Déclaration de la personne responsable du rapport financier intermédiaire
|
French | 225.1 KB | |
| 2025-05-14 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.2 KB | |
| 2025-05-14 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | |
| 2025-04-29 22:05 |
Regulatory News Service
Abivax annonce la fin du recrutement des patients dans le cadre de ses essais d…
|
French | 160.5 KB | |
| 2025-04-29 22:05 |
Regulatory News Service
Abivax annonce la fin du recrutement des patients dans le cadre de ses essais d…
|
French | 41.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Grindeks | Latvia | GRD1R | |
|
Guerbet | France | GBT | |
|
Haemato AG | Germany | HAEK | |
|
Halychpharm | Ukraine | GFARM | |
|
Hamlet BioPharma AB | Sweden | HAMLET | |
|
Harm Reduction Group AB | Sweden | NOHARM | |
|
Heidelberg Pharma AG | Germany | HPHA | |
|
HELLENIC DYNAMICS PLC | United Kingdom | HELD | |
|
HIKMA Pharmaceuticals PLC | United Kingdom | HIK | |
|
H. Lundbeck A | Denmark | HLUN |